STEM CELL THERAPY CONCERTO HEALING is the inevitable objective of stem cell rejuvenation, which is just beautiful integrative with time proven treatments such as acupuncture and entrenched with social science for the... By: Leong Lau … Continue reading →

Whats the difference between adult stem cell taken from body fat and from bone marrow Whats the difference between adult stem cell taken from body fat and from bone marrow? In conversation with Dr Alok Sharma (MS, MCh.) Professor of Neurosurgery Head of Department, LTMG Hospital... By: Neurogen Brain and Spine Institute … Continue reading →

ReNeuron Group Quote more Price: 3.55 Chg: 0.05 Chg %: 1.29% Date: 17:05 Shares in AIM-listed stem cell business ReNeuron Group rose on Tuesday morning after the group unveiled details of progress with the PISCES clinical trial of its ReN001 stem cell therapy for disabled stroke patients. The group said that the primary aim of the study was to test the safety and tolerability of the treatment in ascending doses of the ReN001 cells in patients with moderate to severe functional neurological impairments resulting from their stroke. The secondary aim of the study is to evaluate efficacy measures for the design of future clinical trials with ReN001, including imaging measures as well as a number of tests of sensory, motor and cognitive functions. Interim data from the first nine patients treated in the PISCES study was being presented by the clinical team from Glasgow's Southern General Hospital at the 22nd European Stroke Conference, taking place in London this week, the group said. It added that there was no cell-related or immunological adverse events reported in any of the patients treated and sustained reductions in neurological impairment and spasticity were observed in most patients compared with their stable pre-treatment baseline performance. … Continue reading →

Oldsmar, FL (PRWEB) August 22, 2014 This funding was made through an additional investment in Cryo-Cells cell therapy research affiliate, Saneron CCEL Therapeutics, Inc. in the form of a convertible promissory note purchase agreement. Cryo-Cell is extremely pleased to collaborate with Saneron on several fronts to enable the filing of an IND, which we hope will lead to regenerative therapies using cord blood to treat devastating neurodegenerative diseases such as ALS, David Portnoy, Chairman and Co-CEO of Cryo-Cell, stated. He continued, Although this is only the next step, if Sanerons cord blood product ultimately is successfully approved by the FDA to treat ALS, Saneron will indeed prove to be a very valuable corporate asset for Cryo-Cell. With these funds, Saneron anticipates filing an IND application in the fourth quarter of 2014. The IND for the FDA will be for a Phase I Safety trial enrolling 12 patients that have been diagnosed with ALS, said Nicole Kuzmin-Nichols, President & COO of Saneron. The study will involve the administration of U-CORD-CELL, Sanerons proprietary mononuclear enriched cell fraction of umbilical cord blood to be processed in Cryo-Cells GMP laboratory. Sanerons sponsored preclinical studies using U-CORD-CELL have demonstrated efficacy in various disease models including: … Continue reading →

46 2 Ning -spinal cord injury of C4-C5 (male, 26-year-old) - After stem cell treatment Ning, a 26-year-old guy, happened to fall down from a high level in September, 2006, which led to his spinal cord injury of C4-C5 and remained quadriplegia, incontinence of urination and bowl... By: Stem Cells … Continue reading →